Genetic studies and therapeutic blockade with anti-TL1A antibodies support the critical involvement of TL1A/DR3 pathways in IBD pathogenesis, including chronic mucosal inflammation and fibrosis reversal. The gene discussed is TNFSF15; the disease is inflammatory bowel disease.